Abstract: Castration-resistant prostate cancer is a fatal disease with rapid progress. This malignancy usually presents with metastasis and poor prognosis. This type of disease also often causes 100 % mortality, of which the median survival time is less than20months. Thus, treatment of castration-resistant prostate cancer remains challenging, and the underlying mechanisms of this cancer have yet to be identified. Several new therapies for castration-resistant prostate cancer have been proposed, such as androgen receptor antago-nists, immunotherapeutic drugs, taxanes, antiangiogenic agents, radionuclides, and bone- targeting drugs. These therapies can im-prove the survival time of patients. The advances in the treatment of castration-resistant prostate cancer are briefly reviewed in this ar-ticle.